Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
December 01 2022 - 7:00AM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced
that Steve Hoerter, President and Chief Executive Officer, will
participate in a virtual fireside chat at the JMP Securities
Hematology and Oncology Summit on Tuesday, December 6, 2022 at
10:40 AM ET.
A live webcast of the fireside chat will be available on the
“Events and Presentations” page in the “Investors” section of the
Company’s website at
https://investors.deciphera.com/events-presentations. A replay will
be archived on the Company’s website for 90 days following the
presentation.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering,
developing, and commercializing important new medicines to improve
the lives of people with cancer. We are leveraging our proprietary
switch-control kinase inhibitor platform and deep expertise in
kinase biology to develop a broad portfolio of innovative
medicines. In addition to advancing multiple product candidates
from our platform in clinical studies, QINLOCK® is Deciphera’s
switch control inhibitor for the treatment of fourth-line GIST.
QINLOCK is approved in Australia, Canada, China, the European
Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the
United States. For more information, visit www.deciphera.com and
follow us on LinkedIn and Twitter (@Deciphera).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221201005230/en/
Investor Relations: Maghan Meyers Argot Partners
Deciphera@argotpartners.com 212-600-1902
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Jul 2023 to Jul 2024